These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 28123247)
21. The early effects of intravitreal anti vascular endothelial growth factor agents on intraocular pressure and central corneal thickness. Omay E; Elgin U; Sen E; Yilmazbas P Int Ophthalmol; 2016 Oct; 36(5):665-70. PubMed ID: 26780098 [TBL] [Abstract][Full Text] [Related]
22. Intraocular Pressure Spikes after Aflibercept Intravitreal Injections. El Chehab H; Agard E; Russo A; Boujnah Y; Dot C Ophthalmologica; 2016; 236(1):43-7. PubMed ID: 27409826 [TBL] [Abstract][Full Text] [Related]
23. Intraocular pressure trends after intravitreal injections of anti-vascular endothelial growth factor agents for diabetic macular edema. Al-Abdullah AA; Nowilaty SR; Asghar N; Al-Kharashi AS; Ghazi NG Retina; 2015 Mar; 35(3):440-8. PubMed ID: 25285810 [TBL] [Abstract][Full Text] [Related]
24. Long-term effects of multiple intravitreal antivascular endothelial growth factor injections on intraocular pressure. Kim YJ; Sung KR; Lee KS; Joe SG; Lee JY; Kim JG; Yoon YH Am J Ophthalmol; 2014 Jun; 157(6):1266-1271.e1. PubMed ID: 24561173 [TBL] [Abstract][Full Text] [Related]
25. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Jonas JB; Kreissig I; Degenring R Br J Ophthalmol; 2003 Jan; 87(1):24-7. PubMed ID: 12488256 [TBL] [Abstract][Full Text] [Related]
26. Short-term intraocular pressure changes after intravitreal injection of bevacizumab for retinopathy of prematurity. Kato A; Okamoto Y; Okamoto F; Saito M; Miyazono Y; Oshika T Jpn J Ophthalmol; 2019 May; 63(3):262-268. PubMed ID: 30825009 [TBL] [Abstract][Full Text] [Related]
27. Short-term effects and safety of an acute increase of intraocular pressure after intravitreal bevacizumab injection on corneal endothelial cells. Park J; Lee M BMC Ophthalmol; 2018 Jan; 18(1):17. PubMed ID: 29368595 [TBL] [Abstract][Full Text] [Related]
28. Severe intraocular pressure fluctuation after intravitreal anti-vascular endothelial growth factor injection. Martel JN; Han Y; Lin SC Ophthalmic Surg Lasers Imaging; 2011 Oct; 42 Online():e100-2. PubMed ID: 21986163 [TBL] [Abstract][Full Text] [Related]
29. Acute and chronic optic nerve head biomechanics and intraocular pressure changes in patients receiving multiple intravitreal injections of anti-VEGF. Gómez-Mariscal M; Puerto B; Muñoz-Negrete FJ; de Juan V; Rebolleda G Graefes Arch Clin Exp Ophthalmol; 2019 Oct; 257(10):2221-2231. PubMed ID: 31254051 [TBL] [Abstract][Full Text] [Related]
30. A prospective study of early intraocular pressure changes after a single intravitreal triamcinolone injection. Im L; Allingham RR; Singh I; Stinnett S; Fekrat S J Glaucoma; 2008 Mar; 17(2):128-32. PubMed ID: 18344759 [TBL] [Abstract][Full Text] [Related]
31. Short-term impact of intravitreal ranibizumab injection on axial ocular dimension and intraocular pressure. Goktas A; Goktas S; Atas M; Demircan S; Yurtsever Y Cutan Ocul Toxicol; 2013 Mar; 32(1):23-6. PubMed ID: 22737998 [TBL] [Abstract][Full Text] [Related]
33. The Real-World Effect of Intravitreous Anti-Vascular Endothelial Growth Factor Drugs on Intraocular Pressure: An Analysis Using the IRIS Registry. Atchison EA; Wood KM; Mattox CG; Barry CN; Lum F; MacCumber MW Ophthalmology; 2018 May; 125(5):676-682. PubMed ID: 29336897 [TBL] [Abstract][Full Text] [Related]
34. Management of immediate and sustained intraocular pressure rise associated with intravitreal antivascular endothelial growth factor injection therapy. Aref AA Curr Opin Ophthalmol; 2012 Mar; 23(2):105-10. PubMed ID: 22249237 [TBL] [Abstract][Full Text] [Related]
35. ASSOCIATION BETWEEN NEEDLE SIZE, POSTINJECTION REFLUX, AND INTRAOCULAR PRESSURE SPIKES AFTER INTRAVITREAL INJECTIONS. Pang CE; Mrejen S; Hoang QV; Sorenson JA; Freund KB Retina; 2015 Jul; 35(7):1401-6. PubMed ID: 25650712 [TBL] [Abstract][Full Text] [Related]
36. Incidence of ocular hypertension after intravitreal injection of anti-VEGF agents in the treatment of neovascular AMD. Moraru A; Pînzaru G; Moţoc A; Costin D; Brănişteanu D Rom J Ophthalmol; 2017; 61(3):207-211. PubMed ID: 29450400 [No Abstract] [Full Text] [Related]
37. The short-term effects of intravitreal bevacizumab injection on intraocular pressure, cornea, iridocorneal angle, and anterior chamber. Gumus G; Berhuni M; Ozturkmen C Ther Adv Ophthalmol; 2022; 14():25158414221133772. PubMed ID: 36340047 [TBL] [Abstract][Full Text] [Related]
38. Persistent elevation of intraocular pressure following intravitreal injection of bevacizumab. Segal O; Ferencz JR; Cohen P; Nemet AY; Nesher R Isr Med Assoc J; 2013 Jul; 15(7):352-5. PubMed ID: 23943979 [TBL] [Abstract][Full Text] [Related]
39. [Anti-VEGF therapy in the treatment of anterior segment neovascularization secondary to central retinal vein occlusion]. Kabesha TB; Glacet-Bernard A; Rostaqui O; Souied EH J Fr Ophtalmol; 2015 May; 38(5):414-20. PubMed ID: 25956562 [TBL] [Abstract][Full Text] [Related]